MedTrace Logo

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

NCT03696030 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-23

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent). HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.

Conditions

Interventions

BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given HER2-CAR T cells via intraventricular administration

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Jana L Portnow · City of Hope Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2027-01-24
Completion
2027-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696030 on ClinicalTrials.gov